<DOC>
	<DOCNO>NCT02122536</DOCNO>
	<brief_summary>The aim prospective , randomize , double-blind , intraindividual split face study compare onabotulinumtoxinA incobotulinumtoxinA correction facial wrinkle use 1:1 dose ratio .</brief_summary>
	<brief_title>Split-Face Prospective Study Comparing Botox Xeomin Treatment Facial Wrinkles</brief_title>
	<detailed_description>Patients randomize side face inject onabotulinumtoxinA incobotulinumtoxinA . A total dose 22.5 unit onabotulinumtoxinA 22.5 unit incobotulinumtoxinA administer baseline respect side face . One vial ( 100 MU ) BoNTA reconstitute 2.0 mL 0.9 % sterile saline solution . Similarly , one vial ( 100 MU ) BTXCo reconstitute 2.0 mL 0.9 % sterile saline solution . 2.5 unit respective neurotoxin administer three site crow 's foot area side ( 7.5 unit total one side ) , 2.5 unit two location forehead side ( 5 unit total one side ) , 5.0 unit two location glabella side ( 10 unit total one side ) . The duration study 4 month . The followup visit initial injection 3 day , 2 week , 3 month , 4 month initial treatment . At visit , standardized digital photograph treat facial area take . Both static dynamic photo take region . At conclusion study , three independent raters individually perform blind assessment photograph accord Validated Assessment Scaled Upper Face publish Flynn et al 2012 .</detailed_description>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>male female age 18 old . Previous treatment neuromodulator last 6 month previous brow lift currently pregnant breastfeed history neurological disease deficit active facial skin infection allergy neuromodulators</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>